Lacosamida Dr. Reddys

Lacosamide, the active ingredient in Lacosamida Dr. Reddys, is a sodium channel blocker presented as an intravenous solution for intravenous use. It is indicated as adjunctive therapy for focal (partial‑onset) seizures in patients with epilepsy. The medication is administered under medical supervision in hospital settings.

GNH USA supplies Lacosamida Dr. Reddys as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. Our distribution network reaches major healthcare institutions, ensuring reliable access to high‑quality antiepileptic medicines across Europe, Asia, Africa and the Americas.

Lacosamide is an antiepileptic drug used as adjunctive therapy for focal seizures.

Focal (partial‑onset) seizures: Reduces seizure frequency when added to existing antiepileptic regimens. Epilepsy with focal onset: Improves overall seizure control in patients not fully managed by monotherapy. Adjunctive therapy for epilepsy: Provides additional seizure reduction when combined with other approved agents.

Lacosamide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness. - Nausea: Mild to moderate stomach upset. - Headache: Occasional tension‑type pain. - Somnolence: Increased sleepiness. - Blurred vision: Temporary visual disturbances. - Fatigue: Generalized tiredness.

Serious or Rare Side Effects: - Cardiac arrhythmia (PR‑interval prolongation): May cause conduction abnormalities. - Atrial fibrillation: Irregular heart rhythm episodes. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): Requires immediate medical attention. - Suicidal ideation: New or worsening thoughts of self‑harm. - Respiratory depression: Reduced breathing effort, especially with CNS depressants. - Anaphylaxis: Acute allergic reaction with hives, swelling, or airway compromise.

When using Lacosamide, consider the following safety measures.

Renal impairment: Adjust monitoring as the drug is primarily excreted unchanged by the kidneys. Hepatic impairment: Use caution; liver dysfunction may affect drug metabolism. Cardiac conduction: Perform baseline and periodic ECGs to detect PR‑interval changes. Pregnancy: Safety not established; weigh potential benefits against risks. Concomitant CNS depressants: May increase sedation and respiratory depression. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medications; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): May exacerbate cardiac conduction effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): Can increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., carbamazepine): May reduce lacosamide efficacy.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., phenytoin, valproate): May alter each other's plasma levels. - CNS depressants (e.g., opioids, benzodiazepines): Potential for enhanced sedation. - Alcohol: Can increase dizziness and coordination impairment.